Before it rose to prominence as a vaccine maker, Moderna’s original ambitions were to use its messenger RNA technology — a way to prompt the …
Atea’s fast ascent last year was due to its plan to use a pill originally developed for hepatitis C infections as a treatment for COVID-19. …
After months sticking with its coronavirus vaccine, CureVac has finally given up. CureVac executives had long argued the shot could still play a role in …
Two records set one year ago could fall, as the number of biotech companies going public and the total amount they’ve raised are each on …
Although Pfizer beat Sarepta to start a Phase 3 trial of its gene therapy, the smaller biotech is claiming a milestone in initiating the study …
For the past few years, and especially since the coronavirus pandemic put healthcare in the spotlight, investors have flocked to young biotech companies. Their interest …
In about a year’s time, Moderna went from an ambitious company with unproven technology to one of the world’s most highly valued drug developers. Now, …
A small clinical trial of a once-failed Alzheimer’s drug offered tantalizing but inconclusive hints of benefit, propelling shares in its biotech maker higher by more …
Pfizer is building up its pipeline of experimental cancer medicines, announcing Monday a deal to buy the Cambridge, Massachusetts-based biotech Trillium Therapeutics for nearly $2.3 …
Vertex is best known for its work in cystic fibrosis, having developed four approved medicines that, by the company’s estimates, can treat about 90% of …
Peloton was one of a handful of cancer-focused biotech companies acquired since 2018 by Merck, which has sought to complement its top-selling immunotherapy Keytruda with …
The last several years have seen private equity grow more entrenched in healthcare. Using data from Pitchbook, Healthcare Dive found private equity deals in the …
EQRx, a startup with lofty ambitions to develop competitors to top-selling drugs at much reduced prices, will go public through a merger with a blank-check …
In what has become a common move by large pharmaceutical companies attempting to revitalize their drug research, German healthcare conglomerate Bayer has acquired a small …
The deal with Appia is yet another step in Gilead’s efforts to become an oncology powerhouse — a strategy the company has made clear through …
The FDA’s decision wasn’t surprising to analysts, as “deficiencies” in an approval application have become somewhat of a prelude to rejection. This year alone saw …
Sarepta can claim one of the larger pipelines in biotech, with 42 different programs listed by the developer. Twenty-six of those are gene replacement therapies …
MTPConnect will match the funding by contributing $100,000 in cash per annum and $200,000 per annum in in-kind support over four years, for joint co-funded …
Rapidly growing biotech business, Aptamer Group Ltd, has closed its Series A investment round after attracting international interest, securing $2.2m of funding from overseas investors …
The first of the three shared workspaces has been built in cooperation with Hadassah Medical Centre Ein Kerem and the Jerusalem Development Authority’s BioJerusalem venture. …
